A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.
The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.
The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Firm Allocates Up to $15M in Global Life Science Opportunities, With a Focus on US and China-Based Opportunities
31 AugHot Investor Mandate: VC Firm With UK and USA Offices Seeks Life Science Technologies With Digital Component, Investing Up to $10M
31 AugA venture capital firm with offices in the UK and USA is actively seeking innovative investment opportunities with high potential for growth. With its current fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in the UK, USA, and Canada, but may review those from other geographies on a case by case basis.
The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.
The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Invests in Seed-Stage Healthcare IT and AI-Based Life Sciences Companies, Prefers to Lead Rounds
31 AugA venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their ownership target. The fund is ~75% deployed and expects to make several more investments over the upcoming quarters. The firm will consider opportunities in the United States and Canada.
Within healthcare and life science, the firm is interested in AI-based, non-consumer healthcare IT products. While the firm is open to all indications, the firm is interested in specialist care (i.e., chronic conditions, telehealth), value-based care enablement, behavioral health, elder care, and clinical trial enablement. The consideration of hardware is limited in the healthcare and life science space.
The firm does not have any requirements of the management team. The firm prefers to lead, but will also co-lead and co-invest. They do not require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
RESI Partnering is Open – All Tech Hub Affiliates Get Discounted Rates
28 AugBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Why should tech hubs attend partnering conferences like the Redefining Early Stage Investments (RESI)? Attending RESI provides a unique and valuable platform for incubators, accelerators, universities, non-profits, and government organizations to engage with early-stage life science startups, service providers and investors. It enables attendees like tech hubs to discover new opportunities, build relationships, gain insights, and enhance their overall impact within the startup ecosystem. Tech hubs can get access to:
- Networking Opportunities
- Access to New Technologies
- Deal Flow Generation
- Early Market Trends and Insights
- Investor Engagement
- Brand Visibility
- Learning and Education from LSN staff and sponsorsLife Science Nation’s next RESI conference will be held on September 18-20th in a hybrid format. The first day on the 18th will be at the Boston Park Plaza, followed by the 19-20th with entirely virtual partnering meetings. Don’t miss out on the chance to get added to the RESI partnering platform early! Check out who’s registered. Tech hub staff and startup constituents can save up to $500 off per ticket at RESI Boston. Reach out to Erika Wu to access a discount code.
Muneer Satter, Family Office Investor, Philanthropist, Global Rights Activist to Keynote Global Family Office BioForum
24 AugBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Life Science Nation (LSN) is honored to announce that Mr. Satter will be the keynote speaker at the Global Family Office BioForum Luncheon held as part of the LSN’s Redefining Early Stage Investments (RESI) Boston Partnering Event on September 18th at Park Plaza Hotel in Back Bay and will also be speaking on The Family Office panel in the afternoon.
Mr. Satter manages Satter Investment Management, a family office, and Alerce Investment Management, a private investment firm that invests in Life Science companies. He is a Director of Annexon Biosciences, an autoimmune and neurological diseases company. Additionally, he is currently involved in Alzheon, which is taking an orally administered plaque-preventing drug for treating Alzheimer’s disease through Phase II trials this year.
Mr. Satter was a partner at Goldman Sachs, where he spent 24 years, joining the merchant bank when it had $250 million of assets under management. When he retired, it had $130 Billion of assets under management. He was Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30 billion of assets. He was a senior partner of the Investment Committee and the Chairman of the Risk Committee. As a former Goldman Sachs executive, Mr. Satter is the Vice Chairman of the board of the Goldman Sachs Foundation, and GS Gives, which is part of Goldman Sachs that runs the company’s charitable giving efforts. Mr. Satter is the Investment Committee’s Chairman, overseeing over $1 billion in assets.
He also runs the Satter Foundation, his family’s private foundation. As a philanthropist and global activist, Mr. Satter focuses on organizations he feels make the biggest difference to those who need it the most. Mr. Satter is a big supporter of the United States military and sits on the board and supports the Navy SEAL Foundation. He is also on the Board of Northwestern University.
After attending Northwestern University, he received a JD and MBA from Harvard Law School and Harvard Business School. He is married and has five daughters.

| For more information on the Global Family Office BioForum | Click here |
| If you are a Family Office and would like to attend the Global Family Office BioForum Luncheon | Click here |
View the 50+ Companies Pitching at RESI Boston September 2023
24 AugBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
With less than a month left until RESI Boston September 2023, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at our next conference at the Boston Park Plaza on Monday, September 18, followed by 2 days of virtual partnering on September 19-20!
Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition to the live pitching, all companies will be presenting a poster showcasing their technology in the exhibit hall. We look forward to featuring all of these high-caliber innovations at the upcoming RESI!
Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 600 attendees expected to attend, you can register here!
We are also actively recruiting investors and industry experts to participate in our IPC sessions as judges reviewing the companies and asking them questions validating their company and technology. If interested, please reach out to research@lifesciencenation.com for more information.
RESI Boston September Pitch Companies
Explore NIH Funding Opportunities at RESI Boston Conference!
24 AugBy Candice He, Vice President of Business Development, Global Investment Strategist, LSN
We are excited to announce an exclusive workshop that will be a pivotal highlight of the RESI Boston Conference, happening from September 18-20. Join us and unlock the door to non-dilutive grant funding for your early-stage health innovations
Workshop Topic: Leveraging NIH’s Non-Dilutive Grant Funding
Date: September 18th Time: 11:00 AM ET Location: Boston Park Plaza
Workshop Description
The NIH helps US-based small businesses in their early stages by offering over $1.3 billion in R&D funding through various programs. Small businesses can use NIH funding to generate proof-of-concept data, de-risk their innovation, and attract partners and investors to commercialize their innovation. We support a range of high-impact technologies, such as research tools, diagnostics, digital health, drugs, medical devices, and more. The NIH’s grants do not require equity and can provide the initial funding you need to translate your scientific innovations from an idea to a product. On this panel, representatives of the National Institute on Aging and the National Institute of General Medical Sciences will discuss how to apply for NIH funding, NIH-funded programs and entrepreneurial hubs which support founders across the nation, and unique priority areas in disease areas like Alzheimer’s disease and dementia.
Meet the Panelists
We are happy to introduce the speakers from the NIH who will provide a comprehensive overview of the relevant programs and their requirements:
| Eddie Billingslea Small Business Strategy Coordinator National Institute on Aging |
Joshua HOOKS Program Officer National Institute on Aging |
Rajesh Kumar Program Officer National Institute on Aging |
Get Registered for RESI Boston Conference
This workshop is an opportunity for attendees registered for the RESI Boston September conference. If you haven’t already, register now for RESI to gain access to this invaluable workshop and a multitude of other networking and learning opportunities.
Visit the NIA Exhibit Table
While at the conference, we encourage you to explore the NIA exhibit table. Engage with the experts directly, discover more about NIH Small Business Programs, and explore the vast potential for collaboration and innovation in aging-related research and development.
National Institute on Aging (NIA)
The National Institute on Aging’s (NIA) Small Business Programs manage the largest source of early-stage funding for aging-related R&D. With an annual budget of over $140 million, NIA provides R&D grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Our mission is to develop interventions that prevent or treat Alzheimer’s disease (AD) and AD-related dementias, and we are committed to driving innovation in this critical field.
Join us at the RESI Boston Conference on September 18th at 11:00 AM ET and embark on a transformative journey into the world of non-dilutive grant funding, innovation, and collaboration. Register to meet NIA team and 300+ life science investors to unlock the potential of your health innovations.
Should you have any questions or require further information, please don’t hesitate to contact us at resi@lifesciencenation.com.
We look forward to welcoming you to this exciting event!









